Translational progress shows regulatory constraints on aptamer and nanobody assays, indicating the need for updated guidelines.
Aptamer- and nanobody-based lateral flow assays achieve analytical performance comparable to antibodies, yet remain unapproved as IVDs. Translational progress is constrained by antibody-centric regulatory frameworks rather than assay performance.
No takes yet. Share an insight, caveat, or question.
Monk et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: